Product Highlight - Mezavant XL

Active ingredient: Each tablet contains 1,200 mg mesalazine.
Pharmacodynamic Effects: The Mezavant XL tablet contains a core of mesalazine (5-aminosalicylic acid) 1.2 g formulated in a multi-matrix system which are designed to delay release of mesalazine until exposure to approximately pH 7.
Indication:
• For the induction of clinical and endoscopic remission in patients with mild to moderate, active ulcerative colitis.
• For maintenance of remission.
Dosage & Administration: Mezavant XL is intended for once daily, oral administration. The tablets must not be crushed or chewed and should be taken with food.
• For induction of remission: 2.4 to 4.8 g (two to four tablets) should be taken once daily.
• For maintenance of remission: 2.4 g (two tablets) should be taken once daily.